Topic Review
Omega-3 Polyunsaturated Fatty Acids DHA and EPA
Cardiovascular disease (CVD) that includes myocardial infarction and stroke, is the leading cause of mortality worldwide. Atherosclerosis, the primary underlying cause of CVD, can be controlled by pharmacological and dietary interventions, including n-3 polyunsaturated fatty acid (PUFA) supplementation. n-3 PUFA supplementation, primarily consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has shown promise in reducing atherosclerosis by modulating risk factors, including triglyceride levels and vascular inflammation.
  • 317
  • 23 Nov 2023
Topic Review
Head and Neck Squamous Cell Carcinoma Vaccine
The treatment of unresectable or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) has traditionally relied on chemotherapy or radiotherapy, yielding suboptimal outcomes. The introduction of immunotherapy has significantly improved HNSCC treatment, even if the long-term results cannot be defined as satisfactory. Its mechanism of action aims to counteract the blockade of tumor immune escape. This result can also be obtained by stimulating the immune system with vaccines. 
  • 233
  • 23 Nov 2023
Topic Review
Role of Fibrinogen, Homocysteine and MetS in SSHL
Fibrinogen and homocysteine (HCY) are molecules known to play a role in vascular homeostasis, and their blood levels are often elevated in patients with metabolic syndrome. Recent evidence suggests that sudden sensorineural hearing loss (SSHL) may have a vascular origin. This has led many authors to advocate that fibrinogen, homocysteine, and metabolic syndrome (MetS) may play a direct role in SSHL.
  • 245
  • 23 Nov 2023
Topic Review
Interplay between Thyroid Disorders and T2DM
Thyroid disorders (TD) and diabetes mellitus (DM) are the two endocrinopathies with the highest prevalence in the general population that frequently coexist. Thyroid dysfunction is more common in people with type 2 diabetes mellitus (T2DM) compared to normoglycemic individuals. Untreated TD can impair glycemic control, increasing the risk of diabetes complications. Hyperinsulinemia can affect the morphology of the thyroid gland by promoting the proliferation of thyroid tissue and increasing the size of thyroid nodules. Metformin can confer benefits in both endocrinopathies, while other antidiabetics, such as sulfonylureas, can negatively affect thyroid function. 
  • 180
  • 23 Nov 2023
Topic Review
Poly Adenosine Diphosphate-Ribose Polymerase for Triple-Negative Breast Cancer
The integrity and stability of DNA in breast epithelial tissues are key factors in breast homeostasis. However, carcinogenesis is mostly initiated by DNA damage which is an ongoing process resulting from both endogenous (errors in replication) and exogenous (environmental) assaults to the human genome. Usually, cell repair mechanisms ensure that cells with damaged DNA undergo either repair or apoptosis. Therefore, inhibition of these processes can lead to a buildup of damaged DNA in cells, resulting in apoptosis or senescence of the tumor cells. Poly(ADP-ribose) polymerase (PARP) inhibitors have been closely examined as one of the most exciting and promising “targeted” therapeutic strategies to treat advanced TNBC by preventing cancer cells from repairing themselves. Indeed, it has been demonstrated that 10–20% of total patients diagnosed with TNBC have a mutation in breast cancer susceptibility genes (BRCA)1 or (BRCA)2. BRCA1 and BRCA2 are tumor suppressor genes that are associated with a hereditary predisposition to developing female breast cancer, but their pivotal role in the DNA damage response makes cancer cells harboring such mutations more sensitive to drugs eliciting DNA damage or interfering with DNA repair, such as PARP inhibitors.
  • 175
  • 23 Nov 2023
Topic Review
mRNA and Synthesis-Based Therapeutic Proteins
Recombinant technology has been around for nearly three-quarters of a century and has revolutionized protein therapy. However, the cost of developing recombinant therapeutic proteins and the manufacturing infrastructure keep their cost unaffordable for most patients. Proteins are produced in the body via messenger RNA (mRNA) translation. This process can be readily replicated by administering a chemical nucleic acid product to manufacture the same protein recombinantly. The progress made in creating these proteins ex vivo in a cell-free system also offers a lower-cost option to produce therapeutic proteins.
  • 304
  • 23 Nov 2023
Topic Review
Antibiotics and Steroids on Nasal Microbiomein CRS Patients
The nasal microbiome represents the main environmental factor of the inflammatory process in chronic rhinosinusitis (CRS). Antibiotics and steroids constitute the mainstay of CRS therapies. 
  • 223
  • 23 Nov 2023
Topic Review
Invasive Treatments of Laryngeal Dystonia
Laryngeal dystonia (LD), known or termed as spasmodic dysphonia, is a rare movement disorder with an unknown cause affecting the intrinsic laryngeal muscles. Neurophysiological studies point to perturbed inhibitory processes, while conventional genetic studies reveal fragments of genetic architecture in LD. 
  • 124
  • 22 Nov 2023
Topic Review
Immune Checkpoint Therapy Resistance with SHP2 Inhibition
SHP2 (Src Homology 2 Domain-Containing Phosphatase 2) is a protein tyrosine phosphatase widely expressed in various cell types. SHP2 plays a crucial role in different cellular processes, such as cell proliferation, differentiation, and survival. Aberrant activation of SHP2 has been implicated in multiple human cancers and is considered a promising therapeutic target for treating these malignancies. The PTPN11 gene and functions encode SHP2 as a critical signal transduction regulator that interacts with key signaling molecules in both the RAS/ERK and PD-1/PD-L1 pathways; SHP2 is also implicated in T-cell signaling. SHP2 may be inhibited by molecules that cause allosteric (bind to sites other than the active site and attenuate activation) or orthosteric (bind to the active site and stop activation) inhibition or via potent SHP2 degraders. These inhibitors have anti-proliferative effects in cancer cells and suppress tumor growth in preclinical models. In addition, several SHP2 inhibitors are in clinical trials for cancer treatment.
  • 328
  • 22 Nov 2023
Topic Review
Circulating Tumour Cells in Advanced NSCLC
Non-small cell lung cancer (NSCLC) is one of the deadliest diseases worldwide. Tissue biopsy is the current gold standard for the diagnosis and molecular profiling of NSCLC.
  • 99
  • 22 Nov 2023
  • Page
  • of
  • 1352
Video Production Service